F13A1: Coagulation factor XIII A chain
Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyzes the formation of gamma-glutamyl- epsilon-lysine cross-links between fibrin chains, thus stabilizing the fibrin clot.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on F13A1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Catridecacog | Approved | Novo Nordisk | Protein or peptide | Exogenous proteinCoagulation factor XIII exogenous protein | 0 |
- Factor XIII subunit A deficiency0.81
- Factor XIII, A subunit, deficiency of0.74
- Congenital factor XIII deficiency0.53
- Thrombophilia due to thrombin defect0.48
- Hemorrhage0.46
- Neurodegenerative disease0.39
- Inherited blood coagulation disorder0.37
- Factor XIII deficiency0.34
- Placental retention0.33
- Hyperpituitarism0.31
- Arthropathy0.28
- Adolescent idiopathic scoliosis0.28
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4530, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P00488, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets